세계의 피부사상균성 조진균증 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,944,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,142,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,810,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

주요 조사 결과

• 피부사상균성 조진균증 치료 시장 규모 : 70억 7,470만 달러(2025년 기준)
• 예상 시장 규모 : 106억 280만 달러(2032년)
• 세계 시장 성장률 : 6.0%(2025-2032년 CAGR)

피부사상균성 조진균증 치료 시장 - 보고서 범위

피부사상균성 조진균증 치료는 피부사상균에 의한 일반적인 손톱의 곰팡이 감염을 말합니다. 이 질환은 손톱의 변색, 두꺼워짐, 박리를 유발하며 종종 통증과 불편함을 동반합니다. 피부사상균성 조진균증 치료 시장에는 외용 및 경구용 항진균제, 레이저 치료, 병용 요법 등 다양한 치료 옵션이 있습니다. 치료 시장에는 처방전 기반 및 OTC 제품이 모두 존재하며, 임상 및 가정 환경에서 모두 사용되고 있습니다. 손발톱무좀에 대한 인식이 높아지고 의료 접근성이 향상되면서 시장 확대가 가속화되고 있습니다. 약물 전달 방법의 기술적 진보와 보다 안전하고 효과적인 치료법의 개발은 환자들의 순응도를 높이고 시장의 매력을 높이고 있습니다.

시장 성장 촉진요인

세계 피부사상균성 조진균증 치료 시장은 다양한 요인, 특히 노인 인구, 당뇨병 환자, 면역력이 저하된 환자에서 진균성 손발톱 감염의 발병률 증가 등 다양한 요인에 의해 주도되고 있습니다. 또한, 발 위생에 대한 인식이 높아지고 손톱을 아름답게 가꾸고자 하는 수요도 시장 성장에 기여하고 있습니다. 또한, 테르비나핀과 이트라코나졸과 같은 표적 항진균제 치료제의 출시와 외용제의 발전으로 인해 치료 효과가 크게 향상되고 있습니다. 또한, 원격 피부과와 디지털 헬스 플랫폼의 확대로 특히 원격지나 의료 혜택이 부족한 지역에서 진단율과 치료율이 더욱 향상되고 있습니다.

시장 성장 억제요인

유망한 성장 전망에도 불구하고, 시장은 여러 가지 문제에 직면해 있습니다. 감염의 재발, 치료 기간의 장기화, 환자의 복약 순응도 위반은 여전히 큰 우려 사항입니다. 특정 처방에 따른 고가의 치료비와 일부 지역에서는 보험 적용이 제한적이어서 치료 접근성을 저해하고 있습니다. 또한, 간독성 등 전신 항진균제의 부작용으로 인해 환자 모니터링이 필요하기 때문에 환자와 의료진 모두에게 부담이 될 수 있습니다. 또한, 제품 승인에 대한 규제 장벽과 장기간에 걸친 임상시험의 필요성은 신규 진출기업에게 시장 진입 장벽으로 작용하고 있습니다.

시장 기회

피부사상균성 조진균증 치료 시장은 기술 혁신과 임상적 미충족 수요로 인해 많은 성장 기회가 있습니다. 침투력이 강화되고 독성이 감소된 새로운 항진균제 개발은 제약회사들의 중점 분야입니다. 또한, 레이저를 이용한 광역학 치료의 인기가 높아지면서 부작용이 적은 비침습적 대체 치료법이 제안되고 있습니다. 연구개발에 대한 투자 증가와 제약회사와 피부과 병원의 전략적 제휴는 차세대 치료법의 도입을 촉진할 것으로 예측됩니다. 신흥 경제국은 가처분 소득 증가, 도시화, 의료 인프라의 개선으로 미개발된 잠재력을 가지고 있습니다.

이 보고서는 세계 피부사상균성 조진균증 치료 시장을 조사했으며, 성장 촉진요인, 동향, 기회, 과제 등 시장 역학에 대한 상세한 분석을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• 거시경제 요인
  • 세계의 부문 전망
  • 세계의 GDP 성장 전망
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

• 규제 상황
• 치료 채택 분석
• 질병 역학
• 파이프라인 분석
• 상환 시나리오
• 밸류체인 분석
• 주요 거래와 합병
• PESTLE 분석
• Porter의 Five Forces 분석

제4장 세계의 피부사상균성 조진균증 치료 시장 전망

• 주요 하이라이트
  • 시장 규모와 전년대비 성장
  • 절대적 매출 기회
• 시장 규모 분석과 예측
  • 시장 규모 분석(2019년-2024년)
  • 현재 시장 규모 분석과 예측(2025년-2032년)
• 세계의 피부사상균성 조진균증 치료 시장 전망 : 치료 유형
  • 서론/주요 조사 결과
  • 시장 규모 분석 : 치료 유형별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 치료 유형별(2025년-2032년)
    • 약물 요법
      • 외용 항진균제
      • 경구 항진균제
    • 레이저 요법
    • 광선 역학 요법
    • 병용요법
  • 시장의 매력 분석 : 치료 유형
• 세계의 피부사상균성 조진균증 치료 시장 전망 : 적응증
  • 서론/주요 조사 결과
  • 시장 규모 분석 : 적응증별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 적응증별(2025년-2032년)
    • 원위조하조진균증
    • 표 재성 백색조진균증
    • 근위조하조진균증
    • 칸디다 성 조진균증
    • 전이영양성조진균증
  • 시장의 매력 분석 : 적응증
• 세계의 피부사상균성 조진균증 치료 시장 전망 : 최종사용자
  • 서론/주요 조사 결과
  • 시장 규모 분석 : 최종사용자별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 최종사용자별(2025년-2032년)
    • 기관 판매
      • 병원
      • 피부과 클리닉
    • 소매 판매
      • 소매 약국
      • 드럭스토어
      • 통신 판매 약국 및 온라인 판매
  • 시장의 매력 분석 : 최종사용자

제5장 세계의 피부사상균성 조진균증 치료 시장 전망 : 지역

• 주요 하이라이트
• 시장 규모 분석 : 지역별(2019년-2024년)
• 현재 시장 규모 분석과 예측 : 지역별(2025년-2032년)
  • 북미
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역

제6장 북미의 피부사상균성 조진균증 치료 시장 전망

제7장 유럽의 피부사상균성 조진균증 치료 시장 전망

제8장 동아시아의 피부사상균성 조진균증 치료 시장 전망

제9장 남아시아 및 오세아니아의 피부사상균성 조진균증 치료 시장 전망

제10장 라틴아메리카의 피부사상균성 조진균증 치료 시장 전망

제11장 중동 및 아프리카의 피부사상균성 조진균증 치료 시장 전망

제12장 경쟁 구도

• 시장 구조
  • 경쟁 강도 맵 : 시장별
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근 발전)
  • Bausch Health
  • Galderma SA
  • Novartis AG
  • Pfizer, Inc.
  • Moberg Pharma AB
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Ltd.
  • Medimetriks Pharmaceuticals, Inc.
  • Sanofi SA
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical industries Ltd.
  • Cardinal Health Inc.
  • Viatris Inc.
  • Almirall, SA
  • Vanda Pharmaceuticals Inc.
  • 기타

제13장 부록

LSH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for dermatophytic onychomycosis therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global dermatophytic onychomycosis therapeutics market from 2025 to 2032.

Key Insights:

• Dermatophytic Onychomycosis Therapeutics Market Size (2025E): USD 7,074.7 Million
• Projected Market Value (2032F): USD 10,602.8 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 6.0%

Dermatophytic Onychomycosis Therapeutics Market - Report Scope:

Dermatophytic onychomycosis refers to a common fungal infection of the nail caused by dermatophytes. This condition leads to nail discoloration, thickening, and detachment, often accompanied by pain and discomfort. The market for dermatophytic onychomycosis therapeutics includes a variety of treatment options such as topical and oral antifungal agents, laser therapy, and combination treatments. The therapeutic market caters to both prescription-based and over-the-counter (OTC) products across clinical and home settings. Increasing prevalence of nail fungal infections, coupled with growing awareness and improved healthcare access, is driving market expansion. Technological advancements in drug delivery methods and the development of safer and more effective treatment options are enhancing patient compliance and market appeal.

Market Growth Drivers:

The global dermatophytic onychomycosis therapeutics market is driven by a range of factors, including the rising incidence of fungal nail infections, particularly among the aging population, diabetic patients, and individuals with compromised immune systems. Increasing awareness of foot hygiene and the demand for aesthetic nail appearance are also contributing to market growth. Furthermore, the growing availability of targeted antifungal therapies, such as terbinafine and itraconazole, and advancements in topical drug formulations have significantly improved treatment efficacy. The expansion of teledermatology and digital health platforms has further boosted diagnosis rates and treatment uptake, particularly in remote and underserved regions.

Market Restraints:

Despite promising growth prospects, the market faces several challenges. Recurrence of infection, lengthy treatment durations, and patient non-compliance with medication regimens remain significant concerns. The high cost of certain prescription treatments and limited insurance coverage in some regions can hinder access to therapy. In addition, side effects associated with systemic antifungal medications, such as liver toxicity, require careful patient monitoring, which may deter both patients and providers. Regulatory hurdles for product approval and the need for long-term clinical trials also pose barriers to market entry for new players.

Market Opportunities:

The dermatophytic onychomycosis therapeutics market offers numerous growth opportunities driven by innovation and unmet clinical needs. The development of novel antifungal agents with enhanced penetration and reduced toxicity is a key area of focus for pharmaceutical companies. Additionally, the rising popularity of laser-based and photodynamic therapies presents non-invasive alternatives with minimal side effects. Increased investment in R&D, combined with strategic collaborations between pharmaceutical companies and dermatology clinics, is expected to foster the introduction of next-generation treatments. Emerging economies present untapped potential due to rising disposable income, urbanization, and improving healthcare infrastructure.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the dermatophytic onychomycosis therapeutics market globally?
• Which treatment modalities are gaining traction among patients and providers across various healthcare settings?
• How are technological innovations impacting treatment effectiveness and patient adherence in onychomycosis management?
• Who are the major players in this therapeutic space, and what strategies are they adopting to maintain competitiveness?
• What are the upcoming trends and future outlook for the global dermatophytic onychomycosis therapeutics market?

Competitive Intelligence and Business Strategy:

Key players in the global dermatophytic onychomycosis therapeutics market, including Pfizer Inc., Novartis AG, Bausch Health Companies Inc., and Moberg Pharma AB, focus on expanding their product portfolios through R&D, strategic partnerships, and geographical expansion. Companies are also investing in developing user-friendly topical treatments and oral medications with shorter treatment durations and improved efficacy. Collaborations with dermatology clinics and retail pharmacies, along with patient education campaigns, are enhancing awareness and improving treatment outcomes. Digital marketing and e-commerce platforms are increasingly leveraged to improve product accessibility and consumer reach.

Key Companies Profiled:

• Bausch Health
• Galderma S.A.
• Novartis AG
• Pfizer, Inc.
• Moberg Pharma AB
• Bayer AG
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Medimetriks Pharmaceuticals, Inc.
• Sanofi S.A.
• GlaxoSmithKline Plc.
• Teva Pharmaceutical Industries Ltd.
• Cardinal Health Inc.
• Viatris Inc.
• Almirall, S.A
• Vanda Pharmaceuticals Inc.
• Others

Market Segmentation

By Treatment Type

• Drug-Based Treatment

* Topical Antifungals

* Oral Antifungals

• Laser Therapy
• Photodynamic Therapy
• Combination Therapy

By Indication

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

By End-user

• Institutional Sales
• Hospitals
• Dermatology Clinics
• Retail Sales
• Retail Pharmacies
• Drug Stores
• Mail Order Pharmacies & Online Sales

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Dermatophytic Onychomycosis Therapeutics Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Treatment Adoption Analysis
• 3.3. Disease Epidemiology
• 3.4. Pipeline Analysis
• 3.5. Reimbursement Scenario
• 3.6. Value Chain Analysis
• 3.7. Key Deals and Mergers
• 3.8. PESTLE Analysis
• 3.9. Porter's Five Force Analysis

4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Treatment Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Treatment Type, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
    • 4.3.3.1. Drug-Based Treatment
      • 4.3.3.1.1. Topical Antifungals
      • 4.3.3.1.2. Oral Antifungals
    • 4.3.3.2. Laser Therapy
    • 4.3.3.3. Photodynamic Therapy
    • 4.3.3.4. Combination Therapy
  • 4.3.4. Market Attractiveness Analysis: Treatment Type
• 4.4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Indication
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 4.4.3.1. Distal Subungual Onychomycosis
    • 4.4.3.2. White Superficial Onychomycosis
    • 4.4.3.3. Proximal Subungual Onychomycosis
    • 4.4.3.4. Candidal Onychomycosis
    • 4.4.3.5. Total Dystrophic Onychomycosis
  • 4.4.4. Market Attractiveness Analysis: Indication
• 4.5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: End User
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.5.3.1. Institutional Sales
      • 4.5.3.1.1. Hospitals
      • 4.5.3.1.2. Dermatology Clinics
    • 4.5.3.2. Retail Sales
      • 4.5.3.2.1. Retail Pharmacies
      • 4.5.3.2.2. Drug Stores
      • 4.5.3.2.3. Mail Order Pharmacies & Online Sales
  • 4.5.4. Market Attractiveness Analysis: End User

5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Treatment Type
  • 6.2.3. By Indication
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 6.4.1. Drug-Based Treatment
    • 6.4.1.1. Topical Antifungals
    • 6.4.1.2. Oral Antifungals
  • 6.4.2. Laser Therapy
  • 6.4.3. Photodynamic Therapy
  • 6.4.4. Combination Therapy
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 6.5.1. Distal Subungual Onychomycosis
  • 6.5.2. White Superficial Onychomycosis
  • 6.5.3. Proximal Subungual Onychomycosis
  • 6.5.4. Candidal Onychomycosis
  • 6.5.5. Total Dystrophic Onychomycosis
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.6.1. Institutional Sales
    • 6.6.1.1. Hospitals
    • 6.6.1.2. Dermatology Clinics
  • 6.6.2. Retail Sales
    • 6.6.2.1. Retail Pharmacies
    • 6.6.2.2. Drug Stores
    • 6.6.2.3. Mail Order Pharmacies & Online Sales
• 6.7. Market Attractiveness Analysis

7. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Treatment Type
  • 7.2.3. By Indication
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 7.4.1. Drug-Based Treatment
    • 7.4.1.1. Topical Antifungals
    • 7.4.1.2. Oral Antifungals
  • 7.4.2. Laser Therapy
  • 7.4.3. Photodynamic Therapy
  • 7.4.4. Combination Therapy
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 7.5.1. Distal Subungual Onychomycosis
  • 7.5.2. White Superficial Onychomycosis
  • 7.5.3. Proximal Subungual Onychomycosis
  • 7.5.4. Candidal Onychomycosis
  • 7.5.5. Total Dystrophic Onychomycosis
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.6.1. Institutional Sales
    • 7.6.1.1. Hospitals
    • 7.6.1.2. Dermatology Clinics
  • 7.6.2. Retail Sales
    • 7.6.2.1. Retail Pharmacies
    • 7.6.2.2. Drug Stores
    • 7.6.2.3. Mail Order Pharmacies & Online Sales
• 7.7. Market Attractiveness Analysis

8. East Asia Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Treatment Type
  • 8.2.3. By Indication
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 8.4.1. Drug-Based Treatment
    • 8.4.1.1. Topical Antifungals
    • 8.4.1.2. Oral Antifungals
  • 8.4.2. Laser Therapy
  • 8.4.3. Photodynamic Therapy
  • 8.4.4. Combination Therapy
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 8.5.1. Distal Subungual Onychomycosis
  • 8.5.2. White Superficial Onychomycosis
  • 8.5.3. Proximal Subungual Onychomycosis
  • 8.5.4. Candidal Onychomycosis
  • 8.5.5. Total Dystrophic Onychomycosis
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.6.1. Institutional Sales
    • 8.6.1.1. Hospitals
    • 8.6.1.2. Dermatology Clinics
  • 8.6.2. Retail Sales
    • 8.6.2.1. Retail Pharmacies
    • 8.6.2.2. Drug Stores
    • 8.6.2.3. Mail Order Pharmacies & Online Sales
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Treatment Type
  • 9.2.3. By Indication
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 9.4.1. Drug-Based Treatment
    • 9.4.1.1. Topical Antifungals
    • 9.4.1.2. Oral Antifungals
  • 9.4.2. Laser Therapy
  • 9.4.3. Photodynamic Therapy
  • 9.4.4. Combination Therapy
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 9.5.1. Distal Subungual Onychomycosis
  • 9.5.2. White Superficial Onychomycosis
  • 9.5.3. Proximal Subungual Onychomycosis
  • 9.5.4. Candidal Onychomycosis
  • 9.5.5. Total Dystrophic Onychomycosis
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.6.1. Institutional Sales
    • 9.6.1.1. Hospitals
    • 9.6.1.2. Dermatology Clinics
  • 9.6.2. Retail Sales
    • 9.6.2.1. Retail Pharmacies
    • 9.6.2.2. Drug Stores
    • 9.6.2.3. Mail Order Pharmacies & Online Sales
• 9.7. Market Attractiveness Analysis

10. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Treatment Type
  • 10.2.3. By Indication
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 10.4.1. Drug-Based Treatment
    • 10.4.1.1. Topical Antifungals
    • 10.4.1.2. Oral Antifungals
  • 10.4.2. Laser Therapy
  • 10.4.3. Photodynamic Therapy
  • 10.4.4. Combination Therapy
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 10.5.1. Distal Subungual Onychomycosis
  • 10.5.2. White Superficial Onychomycosis
  • 10.5.3. Proximal Subungual Onychomycosis
  • 10.5.4. Candidal Onychomycosis
  • 10.5.5. Total Dystrophic Onychomycosis
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.6.1. Institutional Sales
    • 10.6.1.1. Hospitals
    • 10.6.1.2. Dermatology Clinics
  • 10.6.2. Retail Sales
    • 10.6.2.1. Retail Pharmacies
    • 10.6.2.2. Drug Stores
    • 10.6.2.3. Mail Order Pharmacies & Online Sales
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Treatment Type
  • 11.2.3. By Indication
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Treatment Type, 2025-2032
  • 11.4.1. Drug-Based Treatment
    • 11.4.1.1. Topical Antifungals
    • 11.4.1.2. Oral Antifungals
  • 11.4.2. Laser Therapy
  • 11.4.3. Photodynamic Therapy
  • 11.4.4. Combination Therapy
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 11.5.1. Distal Subungual Onychomycosis
  • 11.5.2. White Superficial Onychomycosis
  • 11.5.3. Proximal Subungual Onychomycosis
  • 11.5.4. Candidal Onychomycosis
  • 11.5.5. Total Dystrophic Onychomycosis
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.6.1. Institutional Sales
    • 11.6.1.1. Hospitals
    • 11.6.1.2. Dermatology Clinics
  • 11.6.2. Retail Sales
    • 11.6.2.1. Retail Pharmacies
    • 11.6.2.2. Drug Stores
    • 11.6.2.3. Mail Order Pharmacies & Online Sales
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Structure
  • 12.1.1. Competition Intensity Mapping By Market
  • 12.1.2. Competition Dashboard
• 12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.2.1. Bausch Health
    • 12.2.1.1. Overview
    • 12.2.1.2. Segments and Treatment Types
    • 12.2.1.3. Key Financials
    • 12.2.1.4. Market Developments
    • 12.2.1.5. Market Strategy
  • 12.2.2. Galderma S.A.
  • 12.2.3. Novartis AG
  • 12.2.4. Pfizer, Inc.
  • 12.2.5. Moberg Pharma AB
  • 12.2.6. Bayer AG
  • 12.2.7. Dr. Reddy's Laboratories Ltd.
  • 12.2.8. Cipla Ltd.
  • 12.2.9. Medimetriks Pharmaceuticals, Inc.
  • 12.2.10. Sanofi S.A.
  • 12.2.11. GlaxoSmithKline Plc.
  • 12.2.12. Teva Pharmaceutical industries Ltd.
  • 12.2.13. Cardinal Health Inc.
  • 12.2.14. Viatris Inc.
  • 12.2.15. Almirall, S.A
  • 12.2.16. Vanda Pharmaceuticals Inc.
  • 12.2.17. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료